Last reviewed · How we verify
NCT04135781
Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer
Phase 3 trial testing nab paclitaxel in Stomach Cancer in 616 participants. Status unknown.
31 October 2024
Quick facts
| Lead sponsor | Zhejiang Cancer Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 616 |
| Start date | 1 March 2020 |
| Primary completion | 31 October 2024 |
| Estimated completion | 31 October 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- nab paclitaxel
- Tegafur (TEGAFUR) — full drug profile →
- Oxaliplatin (Oxaliplatin) — full drug profile →
- Capecitabine (capecitabine) — full drug profile →
Conditions studied
- Stomach Cancer — all drugs for Stomach Cancer →
Sponsor
Zhejiang Cancer Hospital
Who can join
Adults 18 to 75, any sex, with Stomach Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, open-label phase III study. The treatment was compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX) treating stage Ⅲ gastric cancer as adjuvant setting
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy.
Nawara HM, Afify SM, Hassan G, Zahra MH, et al · · 2021 · cited 57× · PMID 34063205 · DOI 10.3390/biomedicines9050500 -
Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
Cheng X, Wu D, Xu N, Chen L, et al · · 2021 · cited 10× · PMID 33435909 · DOI 10.1186/s12885-020-07772-7 -
Trend of albumin nanoparticles in oncology: a bibliometric analysis of research progress and prospects.
Liu Y, Li Y, Shen W, Li M, et al · · 2024 · cited 6× · PMID 39070787 · DOI 10.3389/fphar.2024.1409163
Verify or expand the search:
- PubMed search for NCT04135781
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of nab paclitaxel
Trials testing the same drug.
- NCT07383922 — A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer · Phase 3 · not yet recruiting
- NCT04153734 — Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC · Phase 2 · not yet recruiting
- NCT03884556 — TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers · Phase 1 · completed
- NCT03703063 — Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer · Phase 1 · unknown
- NCT03377491 — Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinom · Phase 3 · completed
Other recruiting trials for Stomach Cancer
Currently open trials in the same condition.
- NCT07504367 — Large Language Models Assist in Tumor MDT · NA · recruiting
- NCT07310888 — Robotic Gastrectomy With 5th Arm · NA · recruiting
- NCT07070466 — Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA · Phase 2 · recruiting
- NCT06028737 — Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer · Phase 2, PHASE3 · recruiting
- NCT06263088 — EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastroint · NA · recruiting
Other Zhejiang Cancer Hospital trials
Trials by the same sponsor.
- NCT07343479 — Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases · Phase 2 · not yet recruiting
- NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
- NCT07416890 — Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref · Phase 2 · recruiting
- NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
- NCT07330544 — A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Rec · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04135781 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang Cancer Hospital
- Last refreshed: 23 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04135781.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing